The first 癀 class 1 new drug approved clinical sword refers to solid tumors.

Pharma Network September 1st, recently,announced that the company's class 1 chemical innovation drug PZH2111 tablets approved by the State Drug Administration to carry out clinical trials.
is mainly used in the treatment of endo-hepatic bile tube cell carcinoma, urethra cell carcinoma and other advanced solid tumors.
the second half of this year, atwo new chemical class 1 drugs were declared clinical.
PZH2111 tablets obtained clinical implied license PZH2111 tablets (5mg, 25mg) arechemicals with independent intellectual property rights 1 class of innovative drugs.
drug is mainly used to treat advanced solid tumors such as bile tube cell carcinoma and urethra cell carcinoma.
present, PZH2111 tablet project research and development investment of about 27.5 million yuan, the same adaptive drugs in the United States in recent years has been approved by the FDA conditional listing;
PZH2111 tablets are the first new class 1approved clinically in the world.
the second half of this year,a total of two chemical class 1 new drugs declared clinical, respectively, PZH2109 capsules, PZH2111 tablets.
PZH2109 capsules are mainly used to treat non-alcoholic fatty hepatitis (NASH).
2020 to date declared clinical class 1 new drugs are known to be, in addition to PZH2109 capsules, PZH2111 tablets, tabletsthere are a number of new drug projects in the study, the treatment of widespread anxiety new drug PZH1204, the treatment of irritable bowel syndrome new drug ZHP1201, the treatment of osteoarthritis new drug PZH1203 has entered the clinical research stage.
source: CDE, Company Announcement.